Phaseline

Companies › Calico Life Sciences

Calico Life Sciences: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Genitourinary, Oncology, Metabolic and endocrine; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABBV-CLS-484–Phase 2Autosomal Dominant Polycystic Kidney Disease; Advanced Solid Tumor CancerAug 2029
Fosigotifator–Phase 1Vanishing White Matter DiseaseNov 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04777994ABBV-CLS-484Phase 1Advanced Solid Tumor CancerOncologyOct 2026
NCT05757141FosigotifatorPhase 1Vanishing White Matter DiseaseMetabolic and endocrineNov 2027
NCT06902558ABBV-CLS-484Phase 2Autosomal Dominant Polycystic Kidney DiseaseGenitourinaryAug 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Everest Medicines (China) LG Chem Alentis Therapeutics iTeos Therapeutics Shenzhen Kangzhe Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.